Thymosin Beta-4 fragment is a peptide studied in tissue repair, immune, and recovery research. Patients can request a telehealth evaluation through the TelosRX Telehealth Portal to discuss compounded access.
What Is the Thymosin Beta-4 Fragment?
Thymosin Beta-4 (TB-4) is a 43-amino-acid peptide naturally present in human tissue. The fragment forms are studied in preclinical research for tissue repair pathways.
Thymosin Beta-4 fragments are not FDA-approved drugs. They are available through compounding pharmacies under valid prescription.
Common Discussion Points
Patients often raise Thymosin Beta-4 during evaluations for:
- Soft tissue recovery research interest
- Connective tissue support discussions
- Cellular migration research
- Recovery research applications
A licensed provider determines clinical appropriateness individually.
Pre-PCAC July 2026 Regulatory Context
Thymosin Beta-4 fragment is under PCAC review ahead of the July 2026 meeting. Patients interested in compounded access should consult a licensed provider while it remains available.
How TelosRX Handles Thymosin Beta-4 Fragment
TelosRX is an online-first telehealth service. Patient evaluation is asynchronous, and compounded medications are prepared through our licensed pharmacy partner.
- Step 1: Complete an asynchronous telehealth intake at TelosRX.
- Step 2: Licensed provider review.
- Step 3: Prescription issued if clinically appropriate.
- Step 4: Compounded preparation ships discreetly to your door.
Important Compliance Information
Thymosin Beta-4 fragment is not FDA-approved. Compounded preparations are prepared under federal compounding regulations.
Prescriptions require evaluation by a licensed healthcare provider. Approval is not guaranteed. Individual results vary.
TelosRX operates under LegitScript-certified telehealth standards.
Start your private evaluation at TelosRX.